These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 15006020)
1. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence. Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020 [TBL] [Abstract][Full Text] [Related]
2. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. Corcos J; Casey R; Patrick A; Andreou C; Miceli PC; Reiz JL; Harsanyi Z; Darke AC; BJU Int; 2006 Mar; 97(3):520-7. PubMed ID: 16469019 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Kennelly MJ; Lemack GE; Foote JE; Trop CS Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264 [TBL] [Abstract][Full Text] [Related]
4. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. Davila GW; Daugherty CA; Sanders SW; J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842 [TBL] [Abstract][Full Text] [Related]
5. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Aaron LE; Morris TJ; Jahshan P; Reiz JL Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237 [TBL] [Abstract][Full Text] [Related]
6. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Goldenberg MM Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730 [TBL] [Abstract][Full Text] [Related]
7. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH; Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997 [TBL] [Abstract][Full Text] [Related]
8. Transdermal oxybutynin: sticking to the facts. Cartwright R; Cardozo L Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. Gupta SK; Sathyan G J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329 [TBL] [Abstract][Full Text] [Related]
10. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. Preik M; Albrecht D; O'Connell M; Hampel C; Anderson R BJU Int; 2004 Oct; 94(6):821-7. PubMed ID: 15476516 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Wagg A; Wyndaele JJ; Sieber P Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW; J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. Reiz JL; Salem P; Darke AC J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131 [TBL] [Abstract][Full Text] [Related]
18. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476 [TBL] [Abstract][Full Text] [Related]
19. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Takei M; Homma Y; Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]